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Abstract
OBJECTIVE—The purpose of this study was to determine the usefulness of a simple screening 
tool for bleeding disorders in a multisite population of women with menorrhagia.
STUDY DESIGN—Women with menorrhagia between the ages of 18 and 50 years from 6 
geographically diverse US centers underwent hemostatic testing for bleeding disorders, complete 
blood cell count, and ferritin. A questionnaire that contained all elements of the 8-question 
screening tool was administered. Sensitivity of the screening tool, a screening tool with a pictorial 
blood assessment chart (PBAC) score of >185, and a screening tool with serum ferritin were 
calculated for hemostatic disorders.
RESULTS—Two hundred and seventeen women who were identified with a PBAC score of 
≥100 participated in the study. The sensitivity of screening tool was 89% for hemostatic defects, 
and sensitivity increased to 93% and 95% with a serum ferritin level of ≤20 ng/mL and PBAC 
score of >185, respectively.
CONCLUSION—This study confirms the usefulness of a short screening tool for the 
stratification of women with menorrhagia for hemostatic evaluation.
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It is estimated annually that approximately 5% of reproductive-age women seek medical 
attention for menorrhagia.1,2 Underlying hemostatic abnormalities, which include decreased 
von Willebrand factor (VWF), platelet dysfunction, and decreased coagulation factors, are 
found commonly in women with menorrhagia.1,3–5 Yet, most women with menorrhagia seek 
medical attention for their symptoms from gynecologists and primary care physicians, rather 
than from hematologists. Furthermore, few of these women are referred for hemostatic 
evaluation, despite the high prevalence of hemostatic abnormalities in this population6; the 
average delay from onset of bleeding symptoms to diagnosis of a bleeding disorder has been 
reported to be 16 years.7 Barriers to referral for hemostatic evaluation include difficulties 
gynecologists and primary care physicians have in determining whom to refer, lack of 
recognition by gynecologists and primary care physicians of menorrhagia as a symptom of a 
bleeding disorder, the size of the population with complaints of menorrhagia, and the lack of 
simple laboratory tests to screen for hemostatic abnormalities in this population. Given the 
under-recognition and delay in diagnosis of bleeding disorders and the potential for bleeding 
complications with surgery, childbirth or invasive procedures in women with menorrhagia, 
and unidentified bleeding disorders, a standardized screening tool to assist in the 
determination of which women to refer for hemostatic evaluation would be useful for the 
practicing gynecologist. Using data from women with menorrhagia at a single institution, a 
simple easy-to-administer screening tool comprised of 8 questions in 4 categories has been 
developed to help gynecologists assess which women with menorrhagia to refer for a 
comprehensive hemostatic evaluation.8 The purpose of the current study was to test the 
screening tool in a prospectively recruited US multisite population of women with 
menorrhagia. Additionally, we examined potential modifications to the screening tool to 
increase the sensitivity of the identification of women with potential bleeding disorders.
MATERIALS AND METHODS
Study population
Women between the ages of 18 and 50 years at 6 centers in the United States with a 
physician diagnosis of menorrhagia were approached for participation. A pictorial blood 
assessment chart (PBAC) score of ≥100, uterine size ≤12 weeks of gestation, and an 
otherwise negative pelvic examination and normal Papanicolaou smear test within 1 year of 
participation were required for eligibility. Nonsteroidal antiinflammatory agents, aspirin, 
and all antiplatelet medications and herbal agents were discontinued for a minimum of 10 
days before initial laboratory testing. Women who could not discontinue antiplatelet agents 
were excluded from participation. Women with previously diagnosed bleeding disorders and 
those who were on hormonal therapy that included estrogen and/or progesterone 
contraceptives within the last 3 months or who were using an intrauterine device or planning 
pregnancy were also excluded. Women with a history of malignancy, uncontrolled 
hypertension, insulin-dependent diabetes mellitus, chronic liver or renal disease, a seizure 
disorder, venous or arterial thromboembolism, and/or anticoagulation therapy or vascular 
disease were excluded from participation as well. This study was performed as a substudy of 
a US multisite menorrhagia management study.9 The study was approved by the 
Philipp et al. Page 2













institutional review boards of the respective centers and the Centers for Disease Control and 
Prevention. The study was explained to eligible women, and informed consent was obtained.
Four hundred twelve women were identified as eligible to participate; of these, 343 women 
provided informed consent; 80 women withdrew consent. Of the remaining women, 28 did 
not meet PBAC score criteria for menorrhagia. Among the women who underwent 
hemostatic testing, 3 women had incomplete laboratory testing. Analysis was performed on 
217 women with complete questionnaire and laboratory data.9
PBAC
Participants completed the pictorial chart with their next menses after study entry. Blood 
loss was determined by visual self-assessment and scoring of sanitary pad and tampon 
saturation, as previously described.10 All participants were provided with uniform pads and 
tampons to be used during the study. Participants were not receiving any treatment for their 
menorrhagia when the PBAC was recorded. A PBAC score of ≥100 was required for further 
participation in the study.
Laboratory testing
Participants who met study criteria, which included a PBAC score of ≥100, underwent 
testing for low VWF, platelet function defects, and coagulation factor deficiencies that have 
been previously described.1,5 Coagulation testing, including VWF testing, was performed at 
the Centers for Disease Control. Briefly, the activities of factors II, V, VII, VIII, IX, X, and 
XI were assayed by 1-stage methods with appropriate factor-deficient plasmas (Precision 
Biologic, Dartmouth, Nova Scotia, Canada) on an automated analyzer (STA Compact; 
Diagnostica Stago, Parsippany, NJ). VWF antigen was measured on the STA-R Evolution 
(Diagnostica Stago) by latex bead-immunoassay (LIATest; Diagnostica Stago). VWF 
ristocetin cofactor activity was also measured on the STA-R Evolution. Platelet aggregation 
with adenosine triphosphate release and platelet function analyzer (PFA)–100 closure times 
were performed at each site with uniform instrumentation, methods, and agonist 
concentrations.9 PFA-100 closure times were determined with the collagen/epinephrine and 
collagen/adenosine diphosphate cartridges (Dade-Behring, Deerfield, IL). Platelet 
aggregation and adenosine triphosphate release was assessed in platelet-rich plasma in a 
lumiaggregometer with collagen, adenosine diphosphate, arachidonic acid, and epinephrine 
(Chrono-Log Corp, Havertown, PA). Additionally, platelet aggregation was measured using 
ristocetin, and adenosine triphosphate release was measured with thrombin (Chrono-Log 
Corp) as previously described.5,9 A complete blood cell count and serum ferritin test were 
also performed on blood samples from all study participants.
Questionnaire
A questionnaire that elicited information on demographics, medical history, menstrual 
history, bleeding history, and family history was administered in-person to each study 
participant.
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A screening tool was constructed as previously reported,8 based on different combinations 
of symptoms to maximize sensitivity and to minimize the number of women with 
menorrhagia and abnormal hemostasis that were missed by the tool, given the reported delay 
in diagnosis of bleeding disorders and potential complications of undiagnosed bleeding 
disorders. The screening tool contains 8 questions in the following 4 categories: (1) severity 
of menorrhagia, (2) family history of a diagnosed bleeding disorder, (3) personal history of 
excessive bleeding after specific challenges, and (4) history of treatment for anemia. The 
severity of menorrhagia was defined by a duration of menses of ≥7 days and either flooding 
or bleeding through a tampon or napkin in ≤2 hours. A positive family history of a 
diagnosed bleeding disorder required the presence of a known diagnosed bleeding disorder 
such as von Wille-brand disease in a family member. A history of excessive bleeding after a 
challenge was based on the following specific challenges: delivery, miscarriage, surgery, 
tooth extraction, or dental surgery. All elements of the screening tool were contained in the 
questionnaire that was administered prospectively to the study participants. A screening tool 
was considered positive for a study subject if an affirmative response was obtained in any 1 
of the 4 categories (Table 1).
Hemostatic abnormalities
Hemostatic defects were classified as platelet function defects, decreased VWF, coagulation 
factor deficiencies, and/or abnormal PFA-100 results. Platelet function defects were defined 
as defects in platelet aggregation and/or platelet adenosine triphosphate release with ≥1 
agonists. Low VWF was defined as VWF antigen and/or VWF ristocetin cofactor <0%. A 
prolonged PFA-100 was defined if a prolonged PFA-100 was demonstrated in the absence 
of low VWF, platelet function defects, or coagulation factor deficiencies.
Statistical analysis
The data were analyzed with an SAS statistical package (version 9.1; SAS Institute, Cary, 
NC). The means and standard deviations for the age of participants, age at menarche (years), 
duration of menses (days), hemoglobin (grams per deciliter), ferritin (nanograms per 
milliliter) and PBAC scores were calculated. Sensitivity, specificity, positive predictive 
value, and negative predictive value of the screening tool, screening tool with a serum 
ferritin ≤20 ng/mL, and screening tool with a PBAC score of >185, which was a cutoff point 
that was used by Janssen et al,11 was calculated for hemostatic disorders for white and black 
women.
RESULTS
The study included 217 participants between the ages of 18 and 50 years with menorrhagia 
that had been identified by a PBAC score of ≥100; the study was conducted at 6 medical 
centers within the United States. There were 169 white (78%) and 35 black (16%) women 
who participated in the study. Characteristics of the study population are shown in Table 2. 
The mean hemoglobin level was 12.1 ± 1.5 g/dL (7.4 –15.6; n = 155); 56% of women were 
anemic with a hemoglobin level <12 g/dL. The mean serum ferritin level (n = 155) was 20.6 
± 19.8 ng/mL (1–152); the serum ferritin level ≤20 ng/dL in 64% of women.
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On laboratory testing, 71% of the participants (154/217) were found to have ≥1 hemostatic 
abnormalities. Fifty-five percent of the women (120/217) had a platelet function defect; 5% 
of the women (11/217) demonstrated low VWF, and 5% of the women (11/217) had 
coagulation factor deficiencies. Sixty-six percent of the white women (112/169) had ≥1 
hemostatic abnormalities that included 50% of the women (84/169) with platelet function 
defects, whereas 91% of the black women (32/35) had ≥1 hemostatic abnormalities, which 
included 86% with platelet function defects (Table 3).
The screening tool demonstrated 89% sensitivity for hemostatic abnormalities; the positive 
predictive value was 72%. Among 190 women who had a positive screening tool, 137 
women had abnormal hemostatic testing results. The specificity of the screening tool was 
16% for hemostatic defects, and the negative predictive value was 37% (Table 4). When a 
PBAC score of >185 was combined with the screening tool, sensitivity was increased to 
95% for hemostatic defects, and the positive predictive value remained unchanged (Table 4). 
When a low serum ferritin level (≤20 ng/mL) was combined with the screening tool, there 
was a similar increase in sensitivity without a change in positive predictive value. 
Combining both a PBAC score of >185 and serum ferritin level ≤20 ng/mL as additional 
elements of the screening tool did not increase the sensitivities beyond what was observed 
with the PBAC score of >185 and the screening tool. The PFA-100 did not add to the 
sensitivity of the screening tool. For white women, the sensitivity of the screening tool was 
87% for hemostatic and platelet function defects and 70% for low VWF. Sensitivity 
increased to 93% when a PBAC score of >185 was added to the screening tool. Black 
women had sensitivities of 93% and 94%, respectively, for hemostatic and platelet function 
defects, and the sensitivity was 100% for low VWF. All black women who were studied had 
a PBAC score of >185 (Table 5). When serum ferritin level was added to the screening tool, 
the sensitivity of the screening tool increased from 87–90% in white women and 93–100% 
in black women.
COMMENT
This study evaluates, in a multisite US cohort, the usefulness of a short 8-question screening 
instrument for the stratification of women with menorrhagia for hemostatic evaluation. The 
study also demonstrates the utility of a low serum ferritin level to increase the sensitivity of 
the screening tool and confirms the value of a PBAC score of >185 as an adjunct to the 
screening tool. With the use of the screening tool, 8% of women (17/217) in this study who 
had a hemostatic abnormality would not have undergone hemostatic evaluation; 89% of 
women (137/ 154) with a hemostatic abnormality would have been stratified correctly for 
testing. Adding a PBAC score of >185 to the screening tool would have reduced to 4% 
(8/217) the proportion of affected women who were not referred for hemostatic evaluation; 
95% of women (146/ 154) with a hemostatic abnormality would have been stratified 
correctly for testing. Supplementation of the screening tool with a low serum ferritin level 
yielded very similar results: 5% of the women (11/217) with hemostatic defects would have 
been missed; 93% of the women (143/154) with a hemostatic defect would have been 
stratified correctly for evaluation. As previously reported,7 no additional benefit of adding 
the PFA-100 to the screening tool was found.
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In the present study, the specificity was low for the screening tool either alone or in 
combination with a PBAC score of >185 or a low serum ferritin level. One limitation of low 
specificity is the potentially high rate of false-positive screens. However, with a high 
positive predictive value for the screening tool, a low specificity reflects the small number of 
true-negative and false-positive results in this population with a high prevalence of bleeding 
disorders. Although it would be desirable to have a tool with both a high sensitivity (low 
false-negative results) and a high specificity (low false-positive results), there is usually a 
trade-off between missing patients with disease (false-negative results) and having patients 
with false-positive results, depending on the purpose of the tool. Because the screening tool 
was designed to minimize false-negative results and thus to avoid missing women with 
menorrhagia who have bleeding disorders in a population with a high prevalence of these 
disorders, a high sensitivity and low specificity of the screening tool would be appropriate to 
achieve the goal. If the tool were also being used by the hematologist to diagnose bleeding 
disorders in lieu of laboratory testing or possibly to predict bleeding risk, a high specificity 
would be warranted.
Despite differences in study design and study cohorts (which included a lack of inclusion of 
adolescents, study entry criteria, and identification of menorrhagia), results of the current 
multicenter study are similar and confirm those previously determined with the development 
of the screening tool.8 Similar results for the screening tool were obtained whether defining 
menorrhagia based on a PBAC score of ≥100, as was done in this study, or basing 
menorrhagia on a physician diagnosis as was used in the development of the screening tool.8 
The utility of the serum ferritin level as an adjunct to screening for hemostatic abnormalities 
has not been demonstrated previously and may provide a similarly effective, but clinically 
more feasible, supplement to the screening tool than the PBAC score. Although less cost-
efficient than a PBAC score, a serum ferritin level may offer the clinician the possibility of a 
more rapid evaluation and decision for hematologic referral without awaiting a menstrual 
cycle for a prospectively completed PBAC score.
Both a low ferritin level and an elevated PBAC score have been demonstrated to be 
associated with menstrual blood loss of >80 mL per cycle,10–12 which objectively defines 
menorrhagia. The PBAC score has been shown to have 80% sensitivity and specificity for 
menorrhagia.10,11 A combination of low serum ferritin level, clots, and rate of change of 
protection needed during full flow has been reported to have a 60% sensitivity and 86% 
specificity for menorrhagia.12 In this study, approximately two-thirds of women with 
menorrhagia had a low serum ferritin level. We found that a low serum ferritin level and 
increased menstrual flow as measured by PBAC score increased the sensitivity of the 
screening tool for hemostatic defects. In addition, the screening tool incorporates several 
other parameters that are predictive of menorrhagia and include duration of menses more 
than 7 days, flooding, and rate of bleeding through protection. The current study 
demonstrates that multiple clinical parameters that are associated with increased menstrual 
blood loss are useful in screening for hemostatic disorders in this population.
Other efforts to improve the diagnosis of bleeding disorders through bleeding questionnaires 
have resulted in the development of a bleeding score.13–15 The bleeding score, a 
quantification of bleeding symptoms based on a 17-page questionnaire that takes 
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approximately 40 minutes to administer,14 has been condensed recently to a 6-page 
questionnaire.15 However, the bleeding score was developed in patients with known type-1 
von Willebrand disease compared with normal, healthy individuals and has not been 
validated in undiagnosed women with symptoms of menorrhagia or in other hemostatic 
disorders besides type-1 von Willebrand disease. The usefulness of the bleeding score in the 
clinical gynecology or primary care setting to screen women with menorrhagia for 
hemostatic defects, which may often not be type-1 von Willebrand disease in multiracial 
populations, has not been demonstrated.
The screening tool that was used in the current study may be useful to gynecologists and 
primary care providers in the identification of subgroup of women with menorrhagia who 
should be referred for hemostatic evaluation. In contrast with the 0.6–1.3% estimated 
prevalence of von Willebrand disease16–18 and the 1% estimated prevalence of platelet 
function defects19 that was observed in the general nonmenorrhagia population, the 
frequency of these bleeding disorders in women with menorrhagia is high (Table 3). 
Undiagnosed bleeding disorders, which includes von Wille-brand disease and platelet 
function defects in particular, are common in women with menorrhagia and may impact 
women’s lives adversely because of bleeding complications after childbirth and surgery, 
blood transfusions, and chronic iron deficiency anemia.14,20 In addition to preventing the 
bleeding complications of surgery and childbirth with appropriate hemostatic management, 
being able to make the diagnosis of a bleeding disorder, such as a platelet function disorder 
or von Willebrand disease, affords the physician the opportunity to provide effective 
hemostatic management of menorrhagia. Both intranasal desmopressin and tranexamic acid, 
an antifibrinolytic agent, have been demonstrated to reduce menstrual flow in women with 
menorrhagia who have been found to have a bleeding disorder.9 The incorporation of a 
screening program into clinical gynecology practice would simplify and standardize criteria 
for hematologic referral and hemostatic testing in women with menorrhagia. Furthermore, 
universal referral is problematic, given the technical requirements, specialized technical 
expertise, and expense of the comprehensive hemostatic testing (which includes platelet 
function testing) that are required for the diagnosis of bleeding disorders in the menorrhagia 
population. However, several assumptions are implicit with the incorporation of such a 
screening tool, and they must be recognized by providers. Neither a positive screening tool 
itself nor a positive screening tool with the addition of the PBAC score and ferritin level are 
sufficient to diagnose a bleeding disorder; women who have a positive screening result must 
undergo comprehensive hemostatic testing to determine whether they have a bleeding 
disorder. Furthermore, the screening tool is not useful to predict the future risk of excessive 
bleeding. In addition, the screening tool, which was developed and tested in women with 
menorrhagia, may not be valid in patients with other bleeding symptoms. Despite these 
limitations, incorporation of a screening tool for bleeding disorders provides a useful, 
standardized method for the stratification of women with otherwise unexplained 
menorrhagia whose condition is evaluated by gynecologists. These results support the 
incorporation of the screening tool along with either a serum ferritin level and/or the PBAC 
score into clinical practice to help providers identify which women with menorrhagia should 
be referred for hemostatic evaluation.
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TABLE 1
Screening tool
Q1. How many days did your period usually last, from the time bleeding began until it completely stopped?
Q2. How often did you experience a sensation of “flooding” or “gushing” during your period?
Q3. During your period did you ever have bleeding where you would bleed through a tampon or napkin in ≤2 hours?
Q4. Have you ever been treated for anemia?
Q5. Has anyone in your family ever been diagnosed with a bleeding disorder?
Q6. Have you ever had a tooth extracted or had dental surgery?
Q6a. Did you have problem with bleeding after tooth extraction or dental surgery?
Q7. Have you ever had surgery other than dental surgery?
Q7a. Did you have bleeding problem after surgery?
Q8. Have you ever been pregnant?
Q8a. Have you ever had bleeding problem after delivery or after a miscarriage?













Philipp et al. Page 11
TABLE 2
Demographic characteristics of study participants (n = 217)
Variable n Mean ± SD Range
Age, y 36.83 ± 7.1 18.5–49.9
Age at menarche, y 216 12.5 ± 1.5 8–17
Duration of menses, d 214 7.0 ± 3.3 3–33
Race
 White 169 (78%)
 Black 35 (16%)
 Other 13 (6%)
Anemiaa,b 60 (39%)
Hemoglobin, g/dLb 12.1 ± 1.5 7.4–15.6
Ferritin, ng/mLb 20.6 ± 19.8 1–152
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TABLE 3
Frequencies of hemostatic defects in all women (n = 217), white women (n = 169) and black women (n = 35)
Variable All women, n (%) White women, n (%) Black women, n (%)
Platelet function defects 120 (55.3) 84 (50) 30 (86)
Low von Willebrand factora 11 (5.1) 10 (6) 1 (3)
Coagulation factor defect 11 (5.1) 9 (5.3) 0
Platelet function analyzer–100 abnormalitya 12 (5.5) 9 (5.3) 1 (3)
Bleeding disorderb 154 (71.0) 112 (66.3) 32 (91)
a
Prolonged platelet function analyzer–100 time without any other hemostatic defect;
b
Platelet function defects, von Willebrand factor antigen, or von Willebrand factor ristocetin cofactor <50, coagulation defects, or prolonged 
platelet function analyzer–100 time.
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TABLE 4
Sensitivity, specificity, positive predictive value, and negative predictive value for screening tools
Variable Sensitivitya Specificitya Positive predictive valuea Negative predictive valuea
Screening tool
 Bleeding disorderb 89 (83–93) 16 (8–27) 72 (65–78) 37 (19–58)
 Low von Willebrand factor 73 (39–94) 12 (8–17) 4 (2–8) 89 (71–98)
 Platelet function defects 89 (82–94) 14 (8–23) 56 (49–63) 52 (32–71)
Screening tool combined with pictorial blood 
assessment score >185
 Bleeding disorderb 95 (90–98) 6 (2–15) 71 (65–77) 33 (10–65)
 Low von Willebrand factor 91 (59–100) 5 (3–9) 5 (2–9) 92 (62–100)
 Platelet function defects 94 (88–98) 5 (2–12) 55 (48–62) 42 (15–72)
Screening tool combined with ferritin ≤20 ng/mL
 Bleeding disorderb 93 (89–97) 11 (3–19) 72(66–78) 39 (16–61)
 Low von Willebrand factor 91 (59–100) 8 (4–12) 5 (2–8) 94 (84–100)
 Platelet function defects 92 (87–97) 8 (3–14) 55 (48–62) 44 (21–67)
Screening tool combined with platelet function 
analyzer–100
 Bleeding disorderb 89 (84–94) 16 (7–25) 72 (66–78) 37 (19–55)
 Low von Willebrand factor 73 (46–99) 12 (7–16) 4 (1–7) 89 (77–100)
 Platelet function defects 89 (84–95) 14 (7–21) 56 (49–63) 52 (33–71)
a
Data are given as percentage (95% confidence interval);
b
Platelet function defects, von Willebrand factor antigen, or von Willebrand factor ristocetin cofactor <50, coagulation defects, or prolonged 
platelet function analyzer–100 time.
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TABLE 5
Sensitivity of screening tools for white (n = 169) and black (n = 35) women
Sensitivitya
Variable White women Black women
Screening tool
 Hemostatic abnormalityb 87 (72–92) 94 (79–99)
 Low von Willebrand factor 70 (35–93) 100 (3–100)
 Platelet function defects 87 (78–93) 93 (78–99)
Screening tool combined with pictorial blood assessment score >185
 Hemostatic abnormalityb 93 (86–97) 100 (89–100)
 Low von Willebrand factor 90 (56–100) 100 (3–100)
 Platelet function defects 92 (84–97) 100 (88–100)
Screening tool combined with ferritin level ≤20 ng/mL
 Hemostatic abnormalityb 90 (85–96) 100 (89–100)
 Low von Willebrand factor 90 (74–100) 100 (3–100)
 Platelet function defects 88 (81–95) 100 (88–100)
A simple screening tool in combination with a ferritin or a pictorial blood assessment chart is useful for the stratification of women with 
menorrhagia for hemostatic evaluation.
a
Data are given as percentage (95% confidence interval);
b
Platelet function defects, von Willebrand factor antigen, or Von Willebrand factor ristocetin cofactor <50, coagulation defects, and prolonged 
platelet function analyzer–100 time.
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